To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis (PsA)

AbbVie

Status: Completed

Conditions: Work Productivity; Psoriatic Arthritis

Study type: Observational

Funder types: Industry

Identifiers

NCT02028169

P13-518

Details and patient eligibility

About

This post marketing observational study is designed to provide the initial data on work impairment of PsA patients in Turkey, as well as changes in work impairment, life quality and clinical response during treatment with anti-TNF agents.

Enrollment: 120 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Actively working, either full-time or part-time
• Previous confirmed diagnosis of PsA by a rheumatologist
• Patients for whom the physician has initiated PsA treatment with an Anti-TNF in accordance with Turkish Ministry of Health regulations and reimbursement criteria
• Able to provide authorization to use and disclose their health related information

Exclusion criteria

• Patients with a history of an allergic reaction or significant sensitivity to anti-TNF agents
• Patients with possible follow-up problems during the planned study period or patients who may not be compliant to treatment as evaluated by the investigator/treating physician
• Patients participating in any clinical trial of an experimental drug 30 days prior to the baseline visit

Trial design

120 participants in 1 patient group

Participants Receiving Anti-TNF for PsA

Description:

Participants who are actively working (full-time or part-time) with rheumatologist-confirmed PsA for which the physician has initiated treatment with an anti-TNF.